Her main research concerns Ophthalmology, Visual acuity, Surgery, Macular degeneration and Eye disease. While the research belongs to areas of Ophthalmology, she spends her time largely on the problem of Retina, intersecting her research to questions surrounding Nerve fiber. Her biological study spans a wide range of topics, including Clinical trial, Optic neuritis, Audiology and Contrast.
Her Randomized controlled trial study in the realm of Surgery connects with subjects such as Pseudotumor cerebri. Her study in Macular degeneration is interdisciplinary in nature, drawing from both Prospective cohort study and Ranibizumab. Her Ranibizumab research incorporates themes from Lower risk and Confidence interval.
Her primary areas of study are Ophthalmology, Macular degeneration, Visual acuity, Surgery and Internal medicine. As a member of one scientific family, Maureen G. Maguire mostly works in the field of Ophthalmology, focusing on Randomized controlled trial and, on occasion, Placebo. The study incorporates disciplines such as Pro re nata, Prospective cohort study, Incidence and Age related in addition to Macular degeneration.
Her research integrates issues of Diabetic retinopathy, Clinical trial, Optometry, Aflibercept and Ranibizumab in her study of Visual acuity. Her Surgery study combines topics in areas such as Diabetes mellitus, Relative risk and Cohort study. Her Internal medicine study incorporates themes from Gastroenterology and Cardiology.
Her primary areas of investigation include Ophthalmology, Macular degeneration, Internal medicine, Visual acuity and Randomized controlled trial. The various areas that Maureen G. Maguire examines in her Ophthalmology study include Retinopathy of prematurity and Intraclass correlation. Her research in Macular degeneration is mostly focused on Choroidal neovascularization.
Her work in the fields of Internal medicine, such as Odds ratio, Disease and Cohort, intersects with other areas such as Ocular Surface Disease Index. Maureen G. Maguire has researched Visual acuity in several fields, including Diabetic retinopathy, Diabetic macular edema, Ranibizumab and Post-hoc analysis. Her Randomized controlled trial research is multidisciplinary, incorporating elements of Interquartile range, Cohort study, Confidence interval, Placebo and Aflibercept.
Ophthalmology, Visual acuity, Randomized controlled trial, Ranibizumab and Internal medicine are her primary areas of study. Her work on Meibomian gland as part of general Ophthalmology research is frequently linked to Linear mixed effect model, bridging the gap between disciplines. In her research, Atrophy is intimately related to Macular degeneration, which falls under the overarching field of Visual acuity.
Her studies deal with areas such as Placebo, Interquartile range, Aflibercept and Confidence interval as well as Randomized controlled trial. Her Ranibizumab research integrates issues from Clinical trial and Diabetic macular edema. Her Cohort study research is multidisciplinary, incorporating perspectives in Diabetes mellitus, Relative risk and Surgery.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Ranibizumab and bevacizumab for neovascular age-related macular degeneration.
Daniel F Martin;Maureen G Maguire;Gui-shuang Ying.
The New England Journal of Medicine (2011)
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Albert M. Maguire;Francesca Simonelli;Eric A. Pierce;Edward N. Pugh.
The New England Journal of Medicine (2008)
Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results.
Daniel F. Martin;Maureen G. Maguire;Stuart L. Fine;Gui Shuang Ying.
Relation of Visual Function to Retinal Nerve Fiber Layer Thickness in Multiple Sclerosis
Jennifer B. Fisher;Dina A. Jacobs;Clyde E. Markowitz;Steven L. Galetta.
Five-Year Outcomes with Anti-Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration: The Comparison of Age-Related Macular Degeneration Treatments Trials
Maureen G. Maguire;Daniel F. Martin;Gui shuang Ying;Glenn J. Jaffe.
Risk Factors for Corneal Graft Failure and Rejection in the Collaborative Corneal Transplantation Studies
Maureen G. Maguire;Walter J. Stark;John D. Gottsch;R. Doyle Stulting.
Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin - 1-year results of a randomized clinical trial - VIP report no. 1
J. Arnold;D. Kilmartin;J. Olson;S. Neville.
Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials.
Juan E. Grunwald;Ebenezer Daniel;Jiayan Huang;Gui Shuang Ying.
Evaluation of Grid Pattern Photocoagulation for Macular Edema in Central Vein Occlusion: The Central Vein Occlusion Study Group M Report
John G. Clarkson;Elaine Chuang;Donald Gass;Maria Pedroso.
Relationship of Drusen and Abnormalities of the Retinal Pigment Epithelium to the Prognosis of Neovascular Macular Degeneration
Susan B. Bressler;Maureen G. Maguire;Neil M. Bressler;Stuart L. Fine.
Archives of Ophthalmology (1990)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: